导语：体检报告上的箭头，为什么总让人担心
体检结束后，很多人最先关注的不是身高和体重，而是肝功能检查。谷丙转氨酶（ALT）、谷草转氨酶（AST）或γ-谷氨酰转移酶（GGT）旁边一旦出现箭头，人们很容易把它理解成“肝脏不好了”。如果报告上还写着脂肪肝，担忧往往会进一步增加：这些变化会不会继续发展？肝脏还能不能恢复？
肝脏确实很能“扛”。它承担着营养代谢、能量转换、胆汁生成、药物和酒精处理等多项任务，即使已经承受了一段时间的压力，也可能没有明显不适。但肝脏的沉默并不意味着它没有负担。体重增加、血糖血脂异常、饮酒、熬夜、某些药物和长期炎症，都可能让肝细胞反复经历脂肪堆积、氧化压力和损伤修复。
近年来，随着生物合成技术提高了原料的标准化程度和供给稳定性，麦角硫因逐渐进入肝脏健康研究的视野。从代谢功能障碍相关脂肪性肝病、急性肝损伤，到酒精暴露和实验性肝纤维化，多项研究观察到了值得关注的改善线索；早期人体研究也开始关注肝酶变化。麦角硫因可能参与哪些过程？这些研究与普通人的健康有什么关系？答案需要从“肝功能”究竟意味着什么说起。
一、肝功能不是一个数字，而是一整套维持秩序的能力
大众口中的“肝功能”，通常指体检中的一组实验室指标。ALT和AST升高，通常提示肝细胞受损后释放到血液中的酶增多；GGT和碱性磷酸酶的变化，则可帮助医生判断胆道以及酒精、药物等因素的影响；白蛋白、胆红素和凝血相关指标，反映的是肝脏在合成、代谢和排泄方面的能力。医生需要把这些数字与病史、影像、体重、血糖血脂和用药情况放在一起判断。[1,2]
因此，一次转氨酶升高不等于肝功能已经严重受损，转氨酶正常也不能完全排除脂肪沉积或纤维化风险。比某个数字更重要的，是肝脏能否长期完成几件事：及时处理进入体内的营养和外来物质，维持脂肪输入与输出的平衡，在高负荷后降低氧化压力，并让炎症和修复过程适时结束。
健康的肝脏不是永远没有波动，而是在饮食、压力或短期暴露之后，仍有能力回到相对稳定的状态。这种从负担中恢复、重新建立秩序的能力，可以称为肝脏的“恢复力”。麦角硫因之所以受到关注，正是因为它的研究线索同时连接了抗氧化防御、能量代谢、细胞清理和损伤修复。
二、麦角硫因为什么会进入肝脏研究视野
麦角硫因是一种天然含硫氨基酸衍生物。人体不能自行合成，主要从食物中获得，蘑菇是较受关注的膳食来源之一。不过，食物中的含量会受到品种、产地和加工方式影响；随着生物合成技术发展，标准化补充剂也为研究和应用提供了含量更稳定、剂量更可控的选择。人体内还存在专门帮助麦角硫因进入细胞的转运系统。2005年，研究人员鉴定出具有高亲和力的麦角硫因转运蛋白，后来常被称为ETT或OCTN1/SLC22A4。[3,4]
可以把这种转运蛋白理解为细胞膜上的“专用通道”。它帮助麦角硫因被吸收、运输并在部分组织中保留。已有综述认为，麦角硫因具有较好的化学稳定性，能够参与处理活性氧、活性氮及金属离子相关压力，并可能在细胞膜、线粒体和炎症环境中发挥保护作用。[5,6] 2026年一项体外DPPH自由基清除实验还做了定量比较：在同为50 ppm的特定实验条件下，麦角硫因的清除能力约为谷胱甘肽的6.4倍、虾青素的6.5倍、辅酶Q10的46倍。[17] 这些倍数有助于理解其化学抗氧化潜力。
一项双盲、安慰剂对照研究中，45名健康成年人完成试验，分别每日补充5毫克或25毫克麦角硫因，持续7天。研究发现，全血麦角硫因在第7天升高，并在第35天仍可观察到累积；尿液排出量低于摄入量的4%，研究期间未见明显不良反应。[7] 这一步很重要，因为一种成分只有能够被人体吸收并形成可测量的体内暴露，后续的代谢和功能研究才有现实基础。
三、脂肪肝研究：改善线索不只来自“抗氧化”
代谢功能障碍相关脂肪性肝病（MASLD，过去常被称为非酒精性脂肪性肝病）已经成为常见的慢性肝病。2025年发表的一项系统综述与Meta分析汇总2013—2023年中国成年人数据，估计总体患病率约为30.4%。[1] 它往往与超重、胰岛素抵抗、血脂异常和高尿酸等问题共同出现。
脂肪肝并不是肝细胞里简单“多了一点油”。当脂肪酸输入、合成、分解和输出长期失衡，肝细胞会出现脂滴堆积，线粒体承受更大压力，细胞自噬效率也可能下降。自噬可以理解为细胞内部的“清理与回收系统”，它负责处理受损结构和多余物质。清理效率下降后，氧化压力和炎症信号更容易持续。
2024年的动物与细胞研究中，高脂饮食小鼠从第6周起接受约35毫克/千克体重/日的麦角硫因，持续到第24周，每组8只。按体表面积法换算，该动物剂量约相当于成人2.84毫克/千克体重/日，即60千克成人约170毫克/日。与高脂饮食模型组相比，干预组ALT约下降24%、AST约下降16%、总胆固醇约下降37%、低密度脂蛋白胆固醇约下降33%、丙二醛约下降35%、IL-1β约下降54%、IL-6约下降43%，而HDL-C、过氧化氢酶和谷胱甘肽分别约提高109%、147%和124%（根据论文柱状图均值位置估算），多项差异达到p<0.05至p<0.0001。[8] 机制实验提示麦角硫因可通过AMPK通路促进自噬。AMPK像细胞的“能量感应器”，会根据能量状态调整脂肪合成、脂肪酸氧化和细胞清理过程。
2026年发表的另一项动物研究把视角推进到磷脂代谢。研究人员在ApoE缺失小鼠中设置1.7毫克/千克体重和17毫克/千克体重两个口服剂量，连续干预12周。按体表面积法换算，分别约相当于成人0.14和1.38毫克/千克体重/日，即60千克成人约8毫克和83毫克/日。高剂量组改善更为明显，并伴随脂滴减少、肝脂肪变减轻以及PCYT2—磷脂酰乙醇胺—ACOT8相关代谢稳态恢复。[9]
对普通人来说，这一研究方向的意义在于：肝脏状态的改善通常不是靠清除某一种自由基完成的，而是需要脂肪代谢、线粒体供能、细胞清理和炎症控制重新形成协同。体重管理、饮食调整和规律运动仍是肝脏健康管理的基础；在此基础上，标准化的麦角硫因补充剂可以作为一种可量化的日常营养支持，帮助研究者和使用者更清楚地观察摄入量、使用周期与相关指标之间的关系。
四、急性损伤与酒精暴露：帮助肝脏应对高负荷
除了长期代谢压力，肝脏还会面对药物、化学物质和酒精带来的短期高负荷。这些因素可能在较短时间内增加活性氧生成，影响线粒体功能，并启动较强的炎症反应。
2025年的小鼠研究显示，在四氯化碳诱导的急性肝损伤模型中，麦角硫因能够调节LKB1/AMPK/GSK3β/Nrf2通路，并伴随血清ALT、AST、肝组织损伤、炎症和氧化应激相关指标改善；论文图示中的组间差异达到p<0.05至p<0.0001，具有统计学差异。[10] Nrf2可以理解为细胞抗氧化防御的一道“总开关”，启动后会带动多种内源性保护酶表达。
2026年的乙醇喂养小鼠研究设置10、30和50毫克/千克体重三个麦角硫因剂量。按体表面积法换算，分别约相当于成人0.81、2.43和4.05毫克/千克体重，即60千克成人约49、146和243毫克/日。与乙醇模型组相比，50毫克/千克组血清乙醇浓度最多下降54.4%，肝组织谷胱甘肽过氧化物酶活性提高198.2%，白细胞介素-1β水平下降67.1%。研究同时观察到Nrf2相关抗氧化通路和酒精代谢酶活性变化。[11]
减少或避免饮酒，始终是降低酒精相关肝损伤风险的首要措施。麦角硫因相关研究的价值，是帮助我们看清它可能参与哪些抗氧化和代谢防御过程，为日常肝脏健康管理提供研究依据，而不是用营养补充直接抵消饮酒造成的伤害。
五、从肝纤维化到肝硬化，肝脏为什么会越来越“硬”
很多人把肝纤维化和肝硬化当成同一件事。实际上，肝纤维化是肝脏在反复损伤后不断沉积胶原和细胞外基质的过程；当这种瘢痕积累到一定程度，正常结构被明显改造，并影响血流和功能，才可能进入肝硬化阶段。肝硬化是多种慢性肝病长期发展的结果，往往还会增加门静脉高压、肝功能失代偿和肝癌等风险。[2]
这一过程中，肝星状细胞是关键角色。正常情况下，它们相对安静；当肝脏持续受到脂肪、酒精、病毒、毒物或炎症刺激时，肝星状细胞会被激活，转变为大量产生胶原的细胞。适度修复原本是为了封闭损伤，但如果刺激长期存在，修复就可能变成持续瘢痕化。
2023年的小鼠与细胞研究发现，麦角硫因可影响肝星状细胞中的转录因子Foxa3，并伴随α-SMA、胶原相关表达和组织胶原沉积下降，研究图示中的多项差异达到p<0.05至p<0.001，具有统计学差异。[12] 2025年的大鼠研究则设置5毫克/千克体重/日和10毫克/千克体重/日两个剂量，连续干预6周。按体表面积法换算，分别约相当于成人0.81和1.62毫克/千克体重/日，即60千克成人约49和97毫克/日。与模型组相比，血清肝酶、胶原沉积、α-SMA和COL1A1等指标下降，高剂量组改善更明显，并涉及甘油磷脂代谢及TLR4/MyD88/NF-κB信号调节。[13]
这些研究提供了一个重要方向：麦角硫因可能不只影响肝细胞受到损伤的程度，也可能参与损伤之后的修复节奏。当氧化压力和炎症信号得到调节，肝星状细胞持续活化及胶原沉积也可能随之减少。
目前，这条研究线已经把肝星状细胞、胶原沉积、氧化压力和炎症通路等关键环节连接起来，也为后续人体研究选择肝硬度、血清纤维化指标和影像学变化等观察终点提供了较清晰的路线。
六、人体研究走到了哪一步
麦角硫因的人体证据已经从“能否吸收”进入肝酶和代谢指标的进一步研究。健康人研究首先确认了口服后的吸收、血液暴露和总体耐受性。[7] 这为研究剂量、使用周期和目标人群提供了基础。
2026年发布的一项单臂、自身前后对照预印本纳入30名肝酶升高成人，连续30天每日补充60毫克麦角硫因。与基线相比，第30天AST平均下降19.64%（p=0.0082），ALT平均下降21.25%（p=0.0025）；GGT在第15天下降11.49%（p=0.0270），第30天的平均值由87.1 U/L降至71.2 U/L，降幅约18.3%。[14] 这项研究给出了直接面向肝酶升高人群的改善信号，也为后续随机对照试验提供了可参考的指标和效应量。
把现有证据放在一起，可以看到一条逐步向人体转化的路径：健康人研究确认了麦角硫因能够被吸收并形成持续的血液暴露；一项面向肝酶升高人群的早期研究观察到AST、ALT和GGT下降。下一步需要更大样本、安慰剂对照和更长周期的研究，并把肝脂肪含量、肝硬度、血糖血脂及生活方式变化一并纳入，判断这些信号能否重复、能够维持多久，以及哪些人群可能获益更多。
人体转化并不是从零开始。现有研究已经提供了吸收、研究剂量、短期使用周期以及候选肝酶指标等基础信息，也提示代谢性脂肪肝和早期纤维化风险人群可能是值得优先研究的方向。随着随机对照数据增加，麦角硫因对肝功能指标和纤维化相关风险的实际价值将得到更清楚的验证。
七、如果关注麦角硫因，应该看什么
首先要看研究对象。健康人、肝酶升高人群、脂肪肝人群和已经发生肝纤维化的人群，身体状态并不相同，研究结果不能简单相互替代。动物模型中观察到的脂肪变或纤维化改善，也不能直接换算成人体效果。
其次要看原料和剂量。天然食物中的麦角硫因含量会受品种、种植和加工影响；研究使用的通常是成分明确、含量可测的标准化原料。原料菌种、纯度、杂质、稳定性和实际剂量，都会影响研究是否能够重复。欧洲食品安全局曾对合成麦角硫因作为新食品及补充用途进行安全评估，为食品应用提供了一部分安全资料。[15,16]
还要看使用周期和观察终点。30天的肝酶变化与半年、一年的肝脂肪或肝硬度变化不是同一个问题。真正具有长期意义的研究，需要同时观察实验室指标、影像、代谢状态和生活方式，并说明变化能否持续。
这也是SUPER-SYN所关注的稳态问题：不是只追求某一次检查中的数字变化，而是观察肝脏能否在代谢、氧化和炎症压力下逐渐恢复秩序，并保持相对稳定的输出。
八、麦角硫因可以处在肝脏健康日常管理的什么位置
对于大多数脂肪肝和代谢异常人群，体重管理、合理饮食、规律运动、减少或避免饮酒、保证睡眠，以及按医嘱关注血糖和血脂，仍然是改善肝脏状态的基础。[2] 日常管理的关键不是一次“猛补”，而是持续减少肝脏每天面对的代谢和生活方式压力。
在这样的基础上，麦角硫因更适合被理解为一种日常、持续、可量化的营养支持。与食物摄入的自然波动相比，标准化麦角硫因产品可以更准确地控制实际摄入量和使用周期，也便于配合定期复查，观察肝酶、血糖血脂等指标是否发生变化。它的定位是为长期管理增加一层稳定的营养输入，而不能只是发现肝酶异常后的单次临时“补救”。
日常补充也应建立在明确边界之上：研究剂量不是给所有人的建议，补充剂更不能替代减重、戒酒、运动、复查或规范治疗。肝酶异常、脂肪肝、肝纤维化或肝硬化应先明确原因；已经确诊肝病、正在用药、孕期或哺乳期的人群，应先咨询医生或营养专业人员。
结语：改善肝脏状态，关键是帮助身体重新恢复秩序
现有研究让我们看到，麦角硫因与肝脏健康之间已经形成多层次联系：它有专门的转运系统，能够被人体吸收；在代谢性脂肪肝模型中，它与AMPK、自噬和磷脂代谢改善有关；在急性损伤和酒精暴露模型中，它与抗氧化防御和肝酶改善有关；在实验性肝纤维化中，它又连接到肝星状细胞活化和胶原沉积。早期人体研究也出现了肝酶下降信号。
这些证据共同指向的，不是一个简单的“护肝按钮”，而是一套与代谢减负、细胞防御和损伤修复有关的机制网络。麦角硫因可能帮助肝脏在压力之下维持更好的处理能力，也可能为纤维化研究提供新的营养干预线索。
肝脏真正需要的，始终不是短暂掩盖一次指标波动，而是减少持续伤害，让脂肪代谢、炎症反应和组织修复重新回到有序状态。麦角硫因的价值，也应当在这样的长期恢复过程中被理解和验证。
九、麦角硫因与肝脏健康研究证据一览
为便于比较不同研究层级，下面汇总本文涉及的主要原始研究。动物人体等效剂量采用体表面积法粗略换算，小鼠Km值取3、大鼠取6、成人取37，并按60千克成人示例计算。 资料更新至2026年7月30日。
| 文献 | 研究类型与对象 | 剂量/周期 | 主要结果 | 证据强度与局限 |
|---|
| Cheah等，2017[7] | 随机双盲安慰剂对照；45名健康成人 | 5或25 mg/日，7天 | 确认可吸收并形成持续血液暴露；尿排出低于摄入量4%；未见明显不良反应 | 中等：人体随机对照，但终点是吸收与短期安全性，不是肝病疗效 |
| Lv等，2024[8] | 高脂饮食小鼠+AML12细胞 | 35 mg/kg/日；HED约170 mg/日；第6—24周 | 图表估算：ALT约降24%、AST约降16%、TC约降37%、LDL-C约降33%、MDA约降35%、IL-1β约降54%、IL-6约降43%；涉及AMPK/自噬 | 前临床：动物+细胞，可支持机制和剂量探索，不能直接代表人体 |
| Ye等，2026[9] | ApoE缺失高脂饮食小鼠+细胞/多组学 | 1.7、17 mg/kg；HED约8、83 mg/日；12周 | 脂肪变、肝损伤及血脂异常改善，高剂量更明显；指向PCYT2/PE/ACOT8轴；摘要无可核验百分比 | 前临床：动物+细胞/多组学；定量效应需以全文原始数据复核 |
| Zhang等，2025[10] | CCl4急性肝损伤小鼠+AML-12细胞 | 论文设置的实验剂量 | ALT、AST、组织损伤、氧化应激和凋亡指标改善，差异p<0.05至p<0.0001；涉及LKB1/Nrf2 | 前临床：急性模型；公开文本未给出可复核原始均值，不外推为人体疗效 |
| Ding等，2026[11] | 乙醇暴露小鼠 | 10、30、50 mg/kg；HED约49、146、243 mg/日 | 50 mg/kg组血清乙醇最多降54.4%，GSH-Px升198.2%，IL-1β降67.1% | 前临床：有明确剂量反应和效应量 |
| Shu等，2023[12] | 肝纤维化小鼠+肝星状细胞 | 实验性纤维化干预 | α-SMA、胶原相关表达及组织胶原沉积下降；涉及Foxa3 | 前临床：支持抗纤维化机制线索，不等同于治疗或逆转肝硬化 |
| Mao等，2025[13] | 肝纤维化大鼠 | 5、10 mg/kg/日；HED约49、97 mg/日；6周 | ALT、AST、胶原沉积、α-SMA、COL1A1下降；高剂量更明显 | 前临床：支持剂量与机制探索 |
| He等，2026[14] | 单臂自身前后对照预印本；30名肝酶升高成人 | 60 mg/日，30天 | AST降19.64%（p=0.0082），ALT降21.25%（p=0.0025），GGT第15天降11.49%（p=0.0270），第30天约降18.3% | 初步：直接人体信号，但无安慰剂对照、样本小且尚未同行评议 |
参考文献
- Chai X, et al. Epidemiology of metabolic dysfunction-associated steatotic liver disease among adults in China (2013–2023): A systematic review and meta-analysis. World J Gastroenterol. 2025;31(44):112932. doi:10.3748/wjg.v31.i44.112932.
- Rinella ME, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. doi:10.1097/HEP.0000000000000323.
- Gründemann D, et al. Discovery of the ergothioneine transporter. Proc Natl Acad Sci U S A. 2005;102(14):5256-5261. doi:10.1073/pnas.0408624102.
- Schmidt MM, et al. Inventory of the transport mechanisms for the ergothioneine physiome—Known and novel. FEBS Lett. 2022;596(10):1273-1283. doi:10.1002/1873-3468.14329.
- Borodina I, et al. Biology of ergothioneine, an antioxidant nutraceutical. Nutr Res Rev. 2020;33(2):190-217. doi:10.1017/S0954422419000301.
- Kalaras MD, et al. Ergothioneine: an underrecognized dietary micronutrient required for healthy aging? Br J Nutr. 2023;130(6):1041-1046. doi:10.1017/S000711452200304X.
- Cheah IK, et al. Administration of pure ergothioneine to healthy human subjects: uptake, metabolism, and effects on biomarkers of oxidative damage and inflammation. Antioxid Redox Signal. 2017;26(5):193-206. doi:10.1089/ars.2016.6778.
- Lv X, et al. Ergothioneine ameliorates metabolic dysfunction-associated steatotic liver disease by activating autophagy through the AMPK pathway. Lipids Health Dis. 2024;23(1):395. doi:10.1186/s12944-024-02382-9.
- Ye L, et al. Ergothioneine ameliorates HFD-induced hepatic steatosis by restoring phosphatidylethanolamine-ACOT8 homeostasis. Phytomedicine. 2026;158:158238. doi:10.1016/j.phymed.2026.158238.
- Zhang T, et al. Ergothioneine attenuates CCl4-induced acute liver injury in mice by inhibiting oxidative stress and apoptosis via regulating the LKB1/Nrf2 pathway. FASEB J. 2025;39(21):e71175. doi:10.1096/fj.202502156R.
- Ding R, et al. Ergothioneine attenuates alcohol-induced alcoholic fatty liver in mice via antioxidant and alcohol metabolism pathways. J Biochem Mol Toxicol. 2026;40(5):e70899. doi:10.1002/jbt.70899.
- Shu Z, et al. Ergothioneine alleviates liver fibrosis by regulating the expression of the transcription factor Foxa3 in hepatic stellate cells. Food Funct. 2023;14(23):10591-10604. doi:10.1039/D3FO03643J.
- Mao G, et al. Ergothioneine ameliorates hepatic fibrosis by inhibiting oxidative stress and inflammation: involvement of TLR4/MyD88/NF-κB signaling pathway. J Appl Toxicol. 2025;45(3):514-530. doi:10.1002/jat.4728.
- He J, et al. Hepatoprotective efficacy of GeneIII® L-ergothioneine capsules: a self-controlled clinical trial. medRxiv. 2026. doi:10.64898/2025.12.30.25343022.
- EFSA Panel on Dietetic Products, Nutrition and Allergies. Safety of synthetic L-ergothioneine (Ergoneine®) as a novel food pursuant to Regulation (EC) No 258/97. EFSA J. 2016;14(11):4629. doi:10.2903/j.efsa.2016.4629.
- EFSA Panel on Dietetic Products, Nutrition and Allergies. Statement on the safety of synthetic L-ergothioneine as a novel food—supplementary dietary exposure and safety assessment for infants and young children, pregnant and breastfeeding women. EFSA J. 2017;15(11):5060. doi:10.2903/j.efsa.2017.5060.
- He S, et al. Inhibitory effects of ergothioneine on blue light-induced oxidative stress in human lens epithelial cells. Mol Med Rep. 2026;33(5):139. doi:10.3892/mmr.2026.13795.
Introduction: Why Arrows on a Health Check Report Can Feel So Alarming
After a health check, many people look first at their liver function results rather than their height or weight. An arrow beside alanine aminotransferase (ALT), aspartate aminotransferase (AST), or gamma-glutamyl transferase (GGT) can easily be interpreted as a sign that “something is wrong with the liver.” If the report also mentions fatty liver, concern often grows: Will these changes continue to progress? Can the liver still recover?
The liver is remarkably resilient. It performs a wide range of tasks, including nutrient metabolism, energy conversion, bile production, and the processing of medications and alcohol. Even after carrying a substantial burden for some time, it may cause no obvious discomfort. Its silence, however, does not mean an absence of strain. Weight gain, abnormal blood glucose or lipid levels, alcohol consumption, insufficient sleep, certain medications, and chronic inflammation may repeatedly expose liver cells to fat accumulation, oxidative stress, injury, and repair.
In recent years, advances in biosynthesis have improved ingredient standardization and supply stability, bringing ergothioneine into the field of liver health research. Studies ranging from metabolic dysfunction-associated steatotic liver disease and acute liver injury to alcohol exposure and experimental liver fibrosis have reported signals worthy of attention. Early human research has also begun to examine changes in liver enzymes. Which processes might ergothioneine influence? What do these findings mean for everyday health? The answer begins with understanding what “liver function” actually represents.
1. Liver Function Is More Than a Single Number: It Is the Capacity to Maintain Order
In everyday conversation, “liver function” usually refers to a panel of laboratory markers included in a health check. Elevated ALT and AST generally indicate that more enzymes have entered the bloodstream after liver-cell injury. Changes in GGT and alkaline phosphatase can help physicians assess possible effects involving the bile ducts, alcohol, medications, and other factors. Albumin, bilirubin, and coagulation-related markers reflect the liver’s capacity for synthesis, metabolism, and excretion. Physicians interpret these values together with medical history, imaging, body weight, blood glucose and lipid levels, and medication use [1,2].
A single elevation in aminotransferases does not necessarily mean that liver function is already severely impaired, while normal aminotransferases cannot fully exclude fat accumulation or fibrosis risk. More important than any one value is whether the liver can continue to perform several essential tasks over time: process incoming nutrients and external substances promptly, balance fat input and output, reduce oxidative stress after periods of high demand, and bring inflammatory and repair responses to an appropriate close.
A healthy liver may still fluctuate. Its strength lies in its ability to return to a relatively stable state after dietary challenges, stress, or short-term exposure. This ability to recover from burden and re-establish order can be described as liver “resilience.” Ergothioneine has attracted attention because research links it with antioxidant defense, energy metabolism, cellular cleanup, and tissue repair.
2. Why Ergothioneine Has Entered Liver Health Research
Ergothioneine is a naturally occurring sulfur-containing amino acid derivative. The human body cannot synthesize it and obtains it mainly from food, with mushrooms among the most widely studied dietary sources. Food content varies with species, origin, and processing. Advances in biosynthesis have also made standardized supplements available for research and application, offering more consistent content and controllable dosing. The body has a dedicated transport system that helps ergothioneine enter cells. In 2005, researchers identified a high-affinity ergothioneine transporter, commonly referred to as ETT or OCTN1/SLC22A4 [3,4].
This transporter can be understood as a “dedicated channel” in the cell membrane. It supports the absorption and transport of ergothioneine and helps retain it in certain tissues. Reviews suggest that ergothioneine has relatively high chemical stability, can participate in managing stress related to reactive oxygen species, reactive nitrogen species, and metal ions, and may provide protection within cell membranes, mitochondria, and inflammatory environments [5,6]. A 2026 in vitro DPPH free-radical scavenging experiment also made a quantitative comparison. Under the specific test conditions, with each compound at 50 ppm, ergothioneine showed approximately 6.4 times the scavenging capacity of glutathione, 6.5 times that of astaxanthin, and 46 times that of coenzyme Q10 [17]. These ratios help illustrate its chemical antioxidant potential.
In a double-blind, placebo-controlled study, 45 healthy adults completed the trial and received either 5 mg or 25 mg of ergothioneine daily for seven days. Whole-blood ergothioneine increased by day 7, and accumulation remained detectable on day 35. Urinary excretion was less than 4% of intake, and no notable adverse effects were observed during the study [7]. This finding matters because meaningful metabolic and functional research requires an ingredient to be absorbed and to produce measurable exposure in the body.
3. Fatty Liver Research: Improvement Signals Extend Beyond Antioxidant Activity
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly commonly referred to as nonalcoholic fatty liver disease, has become a prevalent chronic liver condition. A systematic review and meta-analysis published in 2025 pooled data from Chinese adults collected between 2013 and 2023 and estimated an overall prevalence of approximately 30.4% [1]. MASLD frequently occurs alongside overweight, insulin resistance, abnormal blood lipids, and elevated uric acid.
Fatty liver involves more than simply having “a little extra fat” inside liver cells. When the input, synthesis, breakdown, and export of fatty acids remain out of balance, lipid droplets accumulate, mitochondria carry greater stress, and autophagic efficiency may decline. Autophagy can be understood as the cell’s internal “cleanup and recycling system,” responsible for processing damaged structures and excess material. When this system becomes less efficient, oxidative stress and inflammatory signaling are more likely to persist.
In a 2024 animal and cell study, mice fed a high-fat diet received approximately 35 mg/kg body weight/day of ergothioneine from week 6 through week 24, with eight mice in each group. Using body-surface-area conversion, this animal dose corresponds to an estimated human equivalent dose of 2.84 mg/kg body weight/day, or approximately 170 mg/day for a 60 kg adult. Compared with the high-fat-diet model group, the intervention group showed estimated reductions of about 24% in ALT, 16% in AST, 37% in total cholesterol, 33% in low-density lipoprotein cholesterol, 35% in malondialdehyde, 54% in IL-1β, and 43% in IL-6. HDL-C, catalase, and glutathione increased by approximately 109%, 147%, and 124%, respectively, based on estimated mean positions in the published bar charts. Multiple differences reached statistical significance from p<0.05 to p<0.0001 [8]. Mechanistic experiments suggested that ergothioneine may promote autophagy through the AMPK pathway. AMPK acts like a cellular “energy sensor,” adjusting fat synthesis, fatty-acid oxidation, and cellular cleanup according to energy status.
Another animal study published in 2026 extended this research to phospholipid metabolism. Researchers administered two oral doses, 1.7 and 17 mg/kg body weight, to ApoE-deficient mice for 12 weeks. Body-surface-area conversion gives estimated human equivalent doses of approximately 0.14 and 1.38 mg/kg body weight/day, or about 8 mg and 83 mg/day for a 60 kg adult. Improvements were more pronounced in the high-dose group and were accompanied by fewer lipid droplets, reduced hepatic steatosis, and restoration of metabolic homeostasis related to the PCYT2–phosphatidylethanolamine–ACOT8 axis [9].
For the general public, the importance of this research direction lies in a broader view of liver improvement. Effective change usually involves coordination among fat metabolism, mitochondrial energy production, cellular cleanup, and inflammation control rather than the removal of one particular free radical. Weight management, dietary adjustment, and regular exercise remain the foundations of liver health management. On this basis, standardized ergothioneine supplements may serve as a quantifiable form of daily nutritional support, allowing researchers and users to observe more clearly how intake, duration of use, and related markers correspond.
4. Acute Injury and Alcohol Exposure: Supporting the Liver Under High Stress
Alongside long-term metabolic pressure, the liver may face short-term high loads from medications, chemicals, and alcohol. These factors can rapidly increase the production of reactive oxygen species, disrupt mitochondrial function, and trigger a strong inflammatory response.
A 2025 mouse study found that, in a carbon tetrachloride-induced acute liver injury model, ergothioneine regulated the LKB1/AMPK/GSK3β/Nrf2 pathway and was accompanied by improvements in serum ALT and AST, liver-tissue injury, inflammation, and oxidative-stress-related markers. Differences between groups shown in the figures ranged from p<0.05 to p<0.0001 and were statistically significant [10]. Nrf2 can be understood as a “master switch” for cellular antioxidant defense. Once activated, it promotes the expression of multiple endogenous protective enzymes.
A 2026 ethanol-fed mouse study tested ergothioneine at 10, 30, and 50 mg/kg body weight. Using body-surface-area conversion, these doses correspond to estimated human equivalent doses of approximately 0.81, 2.43, and 4.05 mg/kg body weight, or about 49, 146, and 243 mg/day for a 60 kg adult. Compared with the ethanol model group, the 50 mg/kg group showed a maximum reduction of 54.4% in serum ethanol concentration, a 198.2% increase in hepatic glutathione peroxidase activity, and a 67.1% reduction in interleukin-1β. The study also observed changes in Nrf2-related antioxidant pathways and the activity of alcohol-metabolizing enzymes [11].
Reducing or avoiding alcohol remains the primary measure for lowering the risk of alcohol-related liver injury. The value of ergothioneine research lies in clarifying the antioxidant and metabolic defense processes in which it may participate and in providing a scientific basis for daily liver health management. Nutritional supplementation should never be used as a way to directly offset the harm caused by drinking.
5. From Liver Fibrosis to Cirrhosis: Why Does the Liver Become Progressively "Stiffer"?
Liver fibrosis and cirrhosis are often treated as the same condition, although they describe different stages. Liver fibrosis is the process by which collagen and extracellular matrix continue to accumulate after repeated injury. Cirrhosis may develop when scar tissue becomes extensive enough to substantially remodel normal structure and impair blood flow and function. It is the long-term outcome of multiple chronic liver diseases and can increase the risks of portal hypertension, hepatic decompensation, and liver cancer [2].
Hepatic stellate cells play a central role in this process. Under normal conditions, they remain relatively quiescent. Persistent stimulation from fat, alcohol, viruses, toxins, or inflammation can activate these cells and transform them into cells that produce large amounts of collagen. Moderate repair initially helps seal an injury, yet prolonged stimulation can turn repair into ongoing scarring.
A 2023 mouse and cell study found that ergothioneine influenced the transcription factor Foxa3 in hepatic stellate cells and was accompanied by reductions in α-SMA, collagen-related expression, and tissue collagen deposition. Multiple differences shown in the figures reached p<0.05 to p<0.001 and were statistically significant [12]. A 2025 rat study tested doses of 5 and 10 mg/kg body weight/day for six weeks. Body-surface-area conversion gives estimated human equivalent doses of approximately 0.81 and 1.62 mg/kg body weight/day, or about 49 and 97 mg/day for a 60 kg adult. Compared with the model group, serum liver enzymes, collagen deposition, α-SMA, COL1A1, and other markers decreased, with more pronounced improvements in the high-dose group. The findings also involved glycerophospholipid metabolism and TLR4/MyD88/NF-κB signaling [13].
These studies point to an important possibility: ergothioneine may influence both the extent of liver-cell injury and the pace of repair afterward. When oxidative stress and inflammatory signaling are regulated, persistent activation of hepatic stellate cells and collagen deposition may also decline.
This research line now connects several key steps, including hepatic stellate-cell activation, collagen deposition, oxidative stress, and inflammatory pathways. It also provides a clearer roadmap for selecting outcomes in future human studies, such as liver stiffness, serum fibrosis markers, and imaging changes.
6. How Far Has Human Research Progressed?
Human evidence on ergothioneine has moved from confirming absorption toward further investigation of liver enzymes and metabolic markers. Research in healthy adults first established oral absorption, measurable blood exposure, and overall tolerability [7]. These findings provide a basis for selecting study doses, duration, and target populations.
A single-arm, self-controlled preprint released in 2026 enrolled 30 adults with elevated liver enzymes who received 60 mg of ergothioneine daily for 30 consecutive days. Compared with baseline, mean AST decreased by 19.64% on day 30 (p=0.0082), and mean ALT decreased by 21.25% (p=0.0025). GGT decreased by 11.49% on day 15 (p=0.0270), and its mean value fell from 87.1 U/L to 71.2 U/L by day 30, a reduction of approximately 18.3% [14]. This study provides a direct improvement signal in people with elevated liver enzymes and offers candidate markers and effect sizes for future randomized controlled trials.
Taken together, the available evidence outlines a gradual path toward human translation. Studies in healthy adults confirm that ergothioneine can be absorbed and produce sustained blood exposure, while an early study in people with elevated liver enzymes observed reductions in AST, ALT, and GGT. The next step requires larger samples, placebo controls, and longer follow-up, together with assessment of liver fat content, liver stiffness, blood glucose and lipids, and lifestyle changes. These studies will need to determine whether the signals can be reproduced, how long they persist, and which populations may benefit most.
Human translation already has a foundation. Existing studies provide initial information on absorption, study doses, short-term duration, and candidate liver-enzyme outcomes. They also suggest that people with metabolic fatty liver or a risk of early fibrosis may be priority populations for future research. As randomized controlled evidence grows, the practical value of ergothioneine for liver function markers and fibrosis-related risk can be evaluated more clearly.
7. What Should You Look for When Evaluating Ergothioneine?
First, consider the study population. Healthy people, individuals with elevated liver enzymes, people with fatty liver, and those who have already developed liver fibrosis represent different physiological states. Results from one group cannot simply substitute for results from another. Improvements in steatosis or fibrosis observed in animal models also cannot be directly converted into expected human effects.
Second, consider the ingredient and dose. Ergothioneine content in natural foods varies with species, cultivation, and processing. Research generally uses standardized materials with a defined identity and measurable content. Ingredient strain, purity, impurities, stability, and the actual administered dose all affect whether findings can be reproduced. The European Food Safety Authority has assessed the safety of synthetic ergothioneine as a novel food and for supplemental use, contributing safety information relevant to food applications [15,16].
Duration and study outcomes also matter. A change in liver enzymes after 30 days addresses a different question from changes in liver fat or stiffness over six months or one year. Research with long-term relevance should evaluate laboratory markers, imaging, metabolic status, and lifestyle together and report whether any change is sustained.
This is also the question of homeostasis that SUPER-SYN focuses on. The goal extends beyond a numerical change on a single test: the key is whether the liver can gradually restore order under metabolic, oxidative, and inflammatory pressure and maintain relatively stable function.
8. Where Can Ergothioneine Fit in Daily Liver Health Management?
For most people with fatty liver or metabolic abnormalities, weight management, a balanced diet, regular exercise, reduced or avoided alcohol intake, sufficient sleep, and medical monitoring of blood glucose and lipids remain the foundations of improving liver status [2]. Effective daily management depends on consistently reducing the metabolic and lifestyle pressures the liver faces, rather than relying on a single intensive round of supplementation.
Within this framework, ergothioneine is best understood as daily, sustained, and quantifiable nutritional support. Compared with the natural variability of food intake, standardized ergothioneine products allow more precise control of actual intake and duration of use. They can also be paired with periodic follow-up to observe possible changes in liver enzymes, blood glucose, blood lipids, and other markers. Their role is to add a stable nutritional input to long-term management, rather than serving as a one-time response after abnormal liver enzymes are discovered.
Daily supplementation should also follow clear boundaries. Research doses are not universal recommendations, and supplements cannot replace weight loss, alcohol cessation, exercise, follow-up testing, or appropriate treatment. The underlying cause of elevated liver enzymes, fatty liver, liver fibrosis, or cirrhosis should be identified first. People with diagnosed liver disease, those taking medication, and those who are pregnant or breastfeeding should consult a physician or qualified nutrition professional before use.
Conclusion: Improving Liver Status Means Helping the Body Restore Order
Current research reveals multiple connections between ergothioneine and liver health. It has a dedicated transport system and can be absorbed by the human body. In metabolic fatty liver models, it has been associated with improvements involving AMPK, autophagy, and phospholipid metabolism. In models of acute injury and alcohol exposure, it has been linked with antioxidant defense and improved liver enzymes. In experimental liver fibrosis, it has also been connected with hepatic stellate-cell activation and collagen deposition. Early human research has now reported signals of declining liver enzymes.
Together, these findings point to a network of mechanisms involving reduced metabolic burden, cellular defense, and injury repair, rather than a single “liver-protection switch.” Ergothioneine may help the liver preserve its capacity to process stress and may provide new nutritional-intervention leads for fibrosis research.
The liver ultimately benefits from reduced ongoing injury and the restoration of orderly fat metabolism, inflammatory responses, and tissue repair. The value of ergothioneine should likewise be understood and verified within this long-term recovery process.
9. Overview of Evidence on Ergothioneine and Liver Health
To facilitate comparison across different levels of evidence, the table below summarizes the major primary studies discussed in this article. Animal doses were roughly converted to human equivalent doses using body-surface-area scaling, with Km values of 3 for mice, 6 for rats, and 37 for adults, illustrated for a 60 kg adult. Information updated through July 30, 2026.
| Reference | Study Type and Subjects | Dose/Duration | Main Findings | Evidence Strength and Limitations |
|---|
| Cheah et al., 2017 [7] | Randomized, double-blind, placebo-controlled; 45 healthy adults | 5 or 25 mg/day for 7 days | Confirmed absorption and sustained blood exposure; urinary excretion below 4% of intake; no notable adverse effects | Moderate: randomized human trial, but the endpoints were absorption and short-term safety rather than efficacy in liver disease |
| Lv et al., 2024 [8] | High-fat-diet mice + AML12 cells | 35 mg/kg/day; HED approx. 170 mg/day; weeks 6–24 | Estimated from figures: ALT ↓ approx. 24%, AST ↓ approx. 16%, TC ↓ approx. 37%, LDL-C ↓ approx. 33%, MDA ↓ approx. 35%, IL-1β ↓ approx. 54%, and IL-6 ↓ approx. 43%; involved AMPK/autophagy | Preclinical: animal + cell study supports mechanism and dose exploration but cannot directly represent human outcomes |
| Ye et al., 2026 [9] | ApoE-deficient mice on a high-fat diet + cells/multi-omics | 1.7 and 17 mg/kg; HED approx. 8 and 83 mg/day; 12 weeks | Improved steatosis, liver injury, and dyslipidemia, with stronger effects at the high dose; implicated the PCYT2/PE/ACOT8 axis; no verifiable percentages in the abstract | Preclinical: animal + cell/multi-omics study; quantitative effects require confirmation from the full original dataset |
| Zhang et al., 2025 [10] | CCl4-induced acute liver injury in mice + AML-12 cells | Experimental doses specified in the paper | Improved ALT, AST, tissue injury, oxidative-stress, and apoptosis markers; differences ranged from p<0.05 to p<0.0001; involved LKB1/Nrf2 | Preclinical: acute model; publicly available text does not provide verifiable raw means, so findings should not be extrapolated as human efficacy |
| Ding et al., 2026 [11] | Ethanol-exposed mice | 10, 30, and 50 mg/kg; HED approx. 49, 146, and 243 mg/day | At 50 mg/kg, serum ethanol fell by up to 54.4%, GSH-Px increased by 198.2%, and IL-1β decreased by 67.1% | Preclinical: clear dose-response pattern and reported effect sizes |
| Shu et al., 2023 [12] | Mice with liver fibrosis + hepatic stellate cells | Experimental fibrosis intervention | Reduced α-SMA, collagen-related expression, and tissue collagen deposition; involved Foxa3 | Preclinical: supports mechanistic signals related to fibrosis; does not demonstrate treatment or reversal of cirrhosis |
| Mao et al., 2025 [13] | Rats with liver fibrosis | 5 and 10 mg/kg/day; HED approx. 49 and 97 mg/day; 6 weeks | Reduced ALT, AST, collagen deposition, α-SMA, and COL1A1; stronger improvement at the high dose | Preclinical: supports dose and mechanism exploration |
| He et al., 2026 [14] | Single-arm, self-controlled preprint; 30 adults with elevated liver enzymes | 60 mg/day for 30 days | AST ↓ 19.64% (p=0.0082), ALT ↓ 21.25% (p=0.0025), GGT ↓ 11.49% on day 15 (p=0.0270), and approx. 18.3% by day 30 | Preliminary: direct human signal, but no placebo control, small sample, and not yet peer-reviewed |
References
- Chai X, et al. Epidemiology of metabolic dysfunction-associated steatotic liver disease among adults in China (2013–2023): A systematic review and meta-analysis. World J Gastroenterol. 2025;31(44):112932. doi:10.3748/wjg.v31.i44.112932.
- Rinella ME, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. doi:10.1097/HEP.0000000000000323.
- Gründemann D, et al. Discovery of the ergothioneine transporter. Proc Natl Acad Sci U S A. 2005;102(14):5256-5261. doi:10.1073/pnas.0408624102.
- Schmidt MM, et al. Inventory of the transport mechanisms for the ergothioneine physiome—Known and novel. FEBS Lett. 2022;596(10):1273-1283. doi:10.1002/1873-3468.14329.
- Borodina I, et al. Biology of ergothioneine, an antioxidant nutraceutical. Nutr Res Rev. 2020;33(2):190-217. doi:10.1017/S0954422419000301.
- Kalaras MD, et al. Ergothioneine: an underrecognized dietary micronutrient required for healthy aging? Br J Nutr. 2023;130(6):1041-1046. doi:10.1017/S000711452200304X.
- Cheah IK, et al. Administration of pure ergothioneine to healthy human subjects: uptake, metabolism, and effects on biomarkers of oxidative damage and inflammation. Antioxid Redox Signal. 2017;26(5):193-206. doi:10.1089/ars.2016.6778.
- Lv X, et al. Ergothioneine ameliorates metabolic dysfunction-associated steatotic liver disease by activating autophagy through the AMPK pathway. Lipids Health Dis. 2024;23(1):395. doi:10.1186/s12944-024-02382-9.
- Ye L, et al. Ergothioneine ameliorates HFD-induced hepatic steatosis by restoring phosphatidylethanolamine-ACOT8 homeostasis. Phytomedicine. 2026;158:158238. doi:10.1016/j.phymed.2026.158238.
- Zhang T, et al. Ergothioneine attenuates CCl4-induced acute liver injury in mice by inhibiting oxidative stress and apoptosis via regulating the LKB1/Nrf2 pathway. FASEB J. 2025;39(21):e71175. doi:10.1096/fj.202502156R.
- Ding R, et al. Ergothioneine attenuates alcohol-induced alcoholic fatty liver in mice via antioxidant and alcohol metabolism pathways. J Biochem Mol Toxicol. 2026;40(5):e70899. doi:10.1002/jbt.70899.
- Shu Z, et al. Ergothioneine alleviates liver fibrosis by regulating the expression of the transcription factor Foxa3 in hepatic stellate cells. Food Funct. 2023;14(23):10591-10604. doi:10.1039/D3FO03643J.
- Mao G, et al. Ergothioneine ameliorates hepatic fibrosis by inhibiting oxidative stress and inflammation: involvement of TLR4/MyD88/NF-κB signaling pathway. J Appl Toxicol. 2025;45(3):514-530. doi:10.1002/jat.4728.
- He J, et al. Hepatoprotective efficacy of GeneIII® L-ergothioneine capsules: a self-controlled clinical trial. medRxiv. 2026. doi:10.64898/2025.12.30.25343022.
- EFSA Panel on Dietetic Products, Nutrition and Allergies. Safety of synthetic L-ergothioneine (Ergoneine®) as a novel food pursuant to Regulation (EC) No 258/97. EFSA J. 2016;14(11):4629. doi:10.2903/j.efsa.2016.4629.
- EFSA Panel on Dietetic Products, Nutrition and Allergies. Statement on the safety of synthetic L-ergothioneine as a novel food—supplementary dietary exposure and safety assessment for infants and young children, pregnant and breastfeeding women. EFSA J. 2017;15(11):5060. doi:10.2903/j.efsa.2017.5060.
- He S, et al. Inhibitory effects of ergothioneine on blue light-induced oxidative stress in human lens epithelial cells. Mol Med Rep. 2026;33(5):139. doi:10.3892/mmr.2026.13795.